Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route

European Journal of Immunology
E MedinaCarlos A Guzmán

Abstract

A common problem in human vaccinology is the limited availability of efficient and non-toxic adjuvants capable of promoting mucosal responses. The potential usefulness of fibronectin-binding protein I (Sfbl) of Streptococcus pyogenes as immunological adjuvant was assessed using ovalbumin (OVA) as a model antigen. Mice were immunized by intranasal route, either with soluble OVA or OVA covalently coupled to Sfbl. Immunization with OVA-Sfbl resulted in the elicitation of about 100-fold higher titers of anti-OVA serum IgG than using OVA alone. The anti-OVA IgG subclass pattern was dominated in both groups of mice by IgG1, followed by IgG2b, IgG2a, and IgG3. Immunization with OVA-Sfbl also resulted in the elicitation of OVA-specific IgA in lung washes (24% of the total IgA), which was absent in mice immunized with OVA alone. Spleen cells from OVA-Sfbl-immunized mice also gave a much stronger proliferative response to restimulation with soluble OVA in vitro. Phenotypic analysis of proliferating cells showed an enrichment in CD4+ T cells, producing a pattern of cytokines (IL-4, IL-5, IL-6 and IL-10) characteristic of Th2-type cells. In contrast to immunization with soluble OVA alone, OVA-Sfbl induced the generation of CD8+ OVA-specifi...Continue Reading

References

Jun 1, 1992·Immunological Reviews·J AnderssonU Andersson
Feb 1, 1992·Immunobiology·J HolmgrenA M Svennerholm
Nov 1, 1991·European Journal of Immunology·O RötzschkeH G Rammensee
Dec 15, 1991·Journal of Immunological Methods·P Matzinger
Feb 1, 1991·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N E Street, T R Mosmann
Feb 1, 1990·The Journal of Experimental Medicine·F R Carbone, M J Bevan
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·B D WalkerR T Schooley
Feb 1, 1988·The Journal of Experimental Medicine·H J de Aizpurua, G J Russell-Jones
Jan 1, 1986·Annual Review of Immunology·B J Underdown, J M Schiff
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·G DouceG Dougan
May 13, 1997·Proceedings of the National Academy of Sciences of the United States of America·S YamamotoJ R McGhee

❮ Previous
Next ❯

Citations

Jun 22, 1999·Immunologic Research·E R Brandt, M F Good
May 21, 2011·Clinical Reviews in Allergy & Immunology·Christopher Chang
Mar 23, 2000·FEMS Immunology and Medical Microbiology·E Medina, C A Guzmán
Aug 1, 2000·Pharmaceutical Science & Technology Today·C D Partidos
Dec 10, 2003·Journal of Clinical Microbiology·Rebecca J TowersGursharan S Chhatwal
Nov 13, 2008·Cytotechnology·D DattaV Chandran
Jul 2, 2003·FEMS Immunology and Medical Microbiology·Kai Schulze, Carlos A Guzmán
Apr 21, 2019·Microbiology Spectrum·Sven HammerschmidtKlaus T Preissner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.